Information about Co-Pay Assistance for Sandostatin® LAR Depot

Changes were made to the Novartis co-pay assistance program for Sandostatin® LAR Depot (octreotide acetate for injectable suspension). This article is intended to help explain these changes to patients who have been enrolled in the previous program, as well as new patients who may be eligible for co-pay assistance.

As part of the Novartis Oncology commitment to patients, we are now providing one Universal Co-Pay Program platform that supports several medications, including Sandostatin LAR Depot. By offering one card, one phone number, and one website for co-pay support, we hope to simplify the process of accessing co-pay support for the medications patients need. With the Universal Co-Pay Program, patients will enroll themselves in the co-pay support program for the medicine they are taking.

Beginning February 1, 2016, all patients will have to enroll themselves on the Sandostatin website,, by going to the Co-Pay Card link in the sidebar menu under How to Get Sandostatin. Another way to enroll is by calling Novartis at 1-877-577-7756. Eligible patients will get a co-pay card, which they can use for their co-pay assistance claims. Physicians will no longer be able to enroll patients or file claims.

Eligible patients will pay a co-pay of no more than $25 per 4-week supply of Sandostatin LAR Depot. Novartis will pay the remainder of the co-pay for their Sandostatin LAR Depot prescription for commercially insured patients, up to $15,000 per calendar year.

Novartis is committed to ensuring a smooth transition for patients. As part of this commitment, beginning mid December 2015, we started contacting all currently enrolled patients and their physicians to provide information regarding the process, as well as Terms and Conditions, for their co-pay support program. We are making every effort to ensure that patients who are eligible for co-pay assistance will not have a gap in their coverage.

Patients may be eligible if they:
• Are at least 18 years of age
• Have been diagnosed with severe diarrhea and flushing symptoms associated with carcinoid tumors (carcinoid syndrome) or acromegaly
• Have commercial insurance
• Are not enrolled in any state or federally funded programs, including but not limited to Medicare, Medicaid, VA, DoD, or Tricare
• Are not paying cash for the full price of the prescription
• Additional Terms and Conditions may apply

Terms and Conditions: This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash payments, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2017. Additional Terms and Conditions may apply.


Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now